Scholarlink

Background <p>Herpes zoster (HZ) and postherpetic neuralgia (PHN) cause substantial clinical and economic burdens, especially in older adults, yet real-world data from China are limited.</p> Methods <p>Using the Jinan Regional Health Information Platform, we conducted a population-based retrospective cohort study (2018–2023) to estimate HZ and PHN incidence (per 1,000 person-years [PY]), recurrence rates, and direct medical costs and factors associated with costs.</p> Results <p>The study included 166,869 patients with HZ. The coverage-adjusted incidence of HZ was 6.80 per 1,000 person-years (PY) overall and ranged from 9.68 per 1,000 PY in the 50–59-year age group to a peak of 16.48 per 1,000 PY in the 70–79-year age group. PHN occurred in 14.2% of HZ patients. The overall coverage-adjusted incidence of PHN was 0.94 per 1,000 PY. HZ recurrence occurred in 0.87% of patients, corresponding to an incidence of 4.26 per 1,000 PY. A total of 72.9% of patients were included in the cost analyses. Median annual costs per patient were CNY 155.2 (interquartile range [IQR]: 50.3–533.1) overall, CNY 126.7 (IQR: 44.4–365.6) for outpatients and CNY 6,290.2 (IQR: 4,038.4–9,093.6) for inpatients. Higher costs were associated with older age, PHN, healthcare facility type, more frequent visits, and length of stay.</p> Conclusions <p>HZ and PHN impose substantial epidemiological and economic burdens in Jinan, with incidence increasing with age, a persistent risk of recurrence, and costs influenced by demographic and healthcare-related factors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Burden of herpes zoster and postherpetic neuralgia in Jinan, China: incidence, recurrence, and direct medical costs, 2018–2023, a population-based retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月24日

查看全文
  • Zemei Zhou,
  • Xiaoqi Wang,
  • Shuai Meng,
  • Lin Tang,
  • Siyu Liu,
  • Qianqian Liu,
  • Xiaoxue Liu,
  • Zundong Yin,
  • Chong Liu,
  • Fuzhen Wang

摘要

Background

Herpes zoster (HZ) and postherpetic neuralgia (PHN) cause substantial clinical and economic burdens, especially in older adults, yet real-world data from China are limited.

Methods

Using the Jinan Regional Health Information Platform, we conducted a population-based retrospective cohort study (2018–2023) to estimate HZ and PHN incidence (per 1,000 person-years [PY]), recurrence rates, and direct medical costs and factors associated with costs.

Results

The study included 166,869 patients with HZ. The coverage-adjusted incidence of HZ was 6.80 per 1,000 person-years (PY) overall and ranged from 9.68 per 1,000 PY in the 50–59-year age group to a peak of 16.48 per 1,000 PY in the 70–79-year age group. PHN occurred in 14.2% of HZ patients. The overall coverage-adjusted incidence of PHN was 0.94 per 1,000 PY. HZ recurrence occurred in 0.87% of patients, corresponding to an incidence of 4.26 per 1,000 PY. A total of 72.9% of patients were included in the cost analyses. Median annual costs per patient were CNY 155.2 (interquartile range [IQR]: 50.3–533.1) overall, CNY 126.7 (IQR: 44.4–365.6) for outpatients and CNY 6,290.2 (IQR: 4,038.4–9,093.6) for inpatients. Higher costs were associated with older age, PHN, healthcare facility type, more frequent visits, and length of stay.

Conclusions

HZ and PHN impose substantial epidemiological and economic burdens in Jinan, with incidence increasing with age, a persistent risk of recurrence, and costs influenced by demographic and healthcare-related factors.